“The stem cells were unable to self-renew, which resulted in long-term and irreversible impairment of tumour growth. In other words, the cancer was permanently shut down.”
Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.
“This is the first step toward clinically applying the principles of cancer stem cell biology to control cancer growth and advance the development of durable cures,” says principal investigator Dr. John Dick about the findings published online today in Nature Medicine.
He talks about the research in this video.
https://www.youtube.com/watch?v=QK7JquljkBc.
Dr. Dick pioneered the cancer stem cell field by first identifying leukemia stem cells (1994) and colon cancer stem cells (2007). He is also renowned for isolating a human blood stem cell in its purest form – as a single stem cell capable of regenerating the entire blood system – paving the way for clinical use (2011). Dr. Dick holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at University Health Network’s Princess Margaret Cancer Centre and McEwen Centre for Regenerative Medicine. He is also a Professor in the Department of Molecular Genetics, University of Toronto, and Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research.
In pre-clinical experiments, the research team replicated human colon cancer in mice to determine if specifically targeting the stem cells was clinically relevant. First, the researchers identified that the gene BMI-1, already implicated in maintaining stem cells in other cancers, is the pivotal regulator of colon cancer stem cells and drives the cycle of self-renewal, proliferation and cell survival. Next, the team used an existing small-molecule inhibitor to successfully block BMI-1, thus demonstrating the clinical relevance of this approach.
Lead author Dr. Antonija Kreso writes: “Inhibiting a recognized regulator of self-renewal is an effective approach to control tumor growth, providing strong evidence for the clinical relevance of self-renewal as a biological process for therapeutic targeting.”
Dr. Dick explains: “When we blocked the BMI-1 pathway, the stem cells were unable to self-renew, which resulted in long-term and irreversible impairment of tumour growth. In other words, the cancer was permanently shut down.”
The Latest Google Headlines on: Colon cancer
[google_news title=”” keyword=”Colon cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on: Colon cancer
- Liver protein could be key to preventing spread of colorectal and other cancers, CWRU researchers sayon April 17, 2024 at 4:52 pm
When secreted from the liver, the protein promotes colon cancer-cell growth. Blocking it could treat the disease.
- Colon Cancer Linked to Mouth Bacteriaon April 15, 2024 at 4:29 am
Genomic research of Fusobacterium nucleatum isolated from colon cancer tumors may help researchers develop future screening tests and cancer vaccines
The Latest Google Headlines on: Therapeutic stem cells
[google_news title=”” keyword=”therapeutic stem cells” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on: Therapeutic stem cells
- New gene therapy eliminates need for bone marrow transplant. Here's how it works.on April 18, 2024 at 3:51 pm
A young Long Island boy is the first in New York state to undergo a new gene therapy for a rare blood disease.
- 8-year-old from Valley Stream becomes first in NY to undergo gene therapy for rare diseaseon April 18, 2024 at 3:14 pm
It involved removing stem cells from Yusef, genetically altering them and then putting them back into his body with the hope they would cure the disease.
- Boy with rare blood disorder receives new life-changing gene therapy treatmenton April 18, 2024 at 3:08 pm
Yusuf Saeed, an 8-year-old born with a rare genetic blood disorder called thalassemia, received a new and transformative gene therapy treatment at Cohen Children’s Medical Center on Long Island.
- 8-year-old boy first in NY to receive FDA-approved gene therapy for rare inherited blood disorderon April 18, 2024 at 1:55 pm
Yusuf is making history as the first patient in the state of New York to undergo an FDA-approved gene therapy for a rare inherited blood disorder called beta-thalassemia.
- Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platformon April 18, 2024 at 1:01 pm
History is coming full circle as induced pluripotent stem (iPS) cell-derived cell therapy maker Shinobi Therapeutics links up with Panasonic and Japan’s Kyoto University, where the first mouse iPS | ...
- Immunotherapy Regenerative Medicine Clinic on Using Stem Cells to Activate the Body's Natural Healing Poweron April 18, 2024 at 10:02 am
Stem cell therapy, a cornerstone of regenerative medicine, has shown immense potential in treating autoimmune diseases, aging conditions, and ...
- AAN 2024: Stem cell therapy for ALS slows disease in some patientson April 18, 2024 at 5:20 am
Treatment with mesenchymal stem cell therapy for ALS was shown to slow disease progression in some but not all patients in a clinical trial.
- Northwell debuts gene therapy with $2.8M price tag for patientson April 18, 2024 at 2:34 am
Northwell Health will announce today that it treated the first patient in New York with Zynteglo, a gene therapy greenlit by the U.S. Food and Drug Administration in 2022. An eight-year-old boy from ...
- Stem Cells Newson April 10, 2024 at 5:00 pm
Feb. 7, 2024 — A tiny microfluidic device can improve cell therapy techniques for spinal cord injury patients. The device can remove a large percentage of stem cells that have not yet fully ...
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Marketon April 10, 2024 at 6:00 am
Somite.ai aims to improve the lives of millions of people by leveraging AI to produce human tissue for cell therapies.